Transforming Growth Factors Type β Inhibit Multibrug Transport in rat Astrocyte Cell Lines

References

• Cheifetz S, Weatherbee J A, Tsang M L-S, Anderson J K, Mole J E, Lucas R, Massague J. The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors. Cell 1987; 48: 409–411
   PubMed Web of Science ®Google Scholar
• Derynck R, Arett J A, Chen E Y, Eaton D H, Bell J R, Assoian R K, Roberts A B, Sporn M B, Goeddel D V. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316: 701–705
   PubMed Web of Science ®Google Scholar
• de Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schluesener H J, Seifert J M, Bodmer S, Fontana A, Hofer E. Complementary DNA from human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor β gene family. EMBO J 1987; 6: 3673–3677
   PubMed Web of Science ®Google Scholar
• Ohta M, Greenberger J S, Anklesaria P, Bassols A, Massague J. Two forms of transforming growth factor-β distinguished by multipotential progenitor cells. Nature 1987; 329: 539–541
   PubMed Web of Science ®Google Scholar
• Segarini P R, Roberts A B, Rosen D M, Seyedin S M. Membrane binding characteristics of two forms of transforming growth factor-β. J Biol Chem 1987; 262: 14655–14661
   PubMed Web of Science ®Google Scholar
• Wozney J M, Rosen V, Celeste A J, Mitsock L M, Whitters M J, Kriz R V, Hemick R M, Wang E A. Novel regulators of bone formation: Molecular clones and activities. Science 1988; 242: 1528–1534
   PubMed Web of Science ®Google Scholar
• Wozney J M. Using purified protein to clone its gene. Methods Enzymol 1990; 182: 738–750
   PubMedGoogle Scholar
• Sporn M B, Roberts A B, Wakefield L M, Crombrugghe B de. Some recent advances in the chemistry and biology of transforming growth factor-β. J Cell Biol 1987; 105: 1039–1045
   PubMed Web of Science ®Google Scholar
• Sporn M B, Roberts A B, Shull J H, Smith J M, Ward J M, Sodek J. Polypeptide transforming growth factors isolated from bovine sources used for wound-healing in vivo. Science 1983; 219: 1329–1331
   PubMed Web of Science ®Google Scholar
• Schluesener H J, Meyermann R. TGF-β1, β2, β1, 2 and the bone morphogenetic protein BMP-2: members of the transforming growth factor type β supergene family with different morphogenetic effects on rat astrocyte cultures. Autoimmunity 1991, in press
   Google Scholar
• Zuber P, Kuppner M C, de Tribolet N. Transforming growth factor-β2 down-regulates HLA-DR antigen expression on human malignant glioma cells. Eur J Immunol 1989; 18: 1623–1626
   Google Scholar
• Schluesener H J. Transforming growth factor type β1 and β2 suppress rat astrocyte autoantigen presentation and antagonize hyperinduction of class II major histocompatibility complex antigen expression by interferon-gamma and tumor necrosis factor-alpha. J Neuroimmunol 1990; 27: 41–47
   PubMedGoogle Scholar
• Schluesener H J, Meyermann R. Spontaneous expression of multidrug transporter P-glycoprotein in human glial tumor cells associated with sensitivity to morphogenetic effects of TGF-β1, β2, and β1, 2. Acta Neuropathologica 1991, in press
   PubMedGoogle Scholar
• Toru-Delbauffe D, Baghdassarian-Chalaya D, Gavaret J M, Coustin F, Pomerance M, Pierre M. Effects of transforming growth factor β1, on astroglial cells in culture. J Neurochem 1990; 54: 1056–1061
   PubMedGoogle Scholar
• Endicott J A, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137–171
   PubMed Web of Science ®Google Scholar
• Gottesman M M, Pastan I. The multidrug transporter, a double-edged sword. J BiolChem 1988; 263: 12163–12166
   PubMed Web of Science ®Google Scholar
• Juranka P F, Zastawny R L, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989; 3: 2583–2592
   PubMed Web of Science ®Google Scholar
• Roninson I B, Chin J E, Choi K, Gros P, Housman D E, Fojo A, Shen D-W, Gottesman M M, Pastan I. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 4538–4542
   PubMed Web of Science ®Google Scholar
• Bourhis J, Benard J, Hartmann O, Boccon-Gibod L, Lemerle J, Riou G. Correlation of mdr I gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 1989; 81: 1401–1405
   PubMed Web of Science ®Google Scholar
• Dalton W S, Grogan T M, Meltzer P S, Scheper R J, Durie B GM, Taylor C W, Miller T P, Salmon S E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415–424
   PubMed Web of Science ®Google Scholar
• Fojo A T, Ueda K, Slalom D J, Poplack D G, Gottesman M M, Pastan I. Expression of multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265–269
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O'Brien J, Casals D, Rittman-Grauer L, Biedler J L, Melamed M R, Bertino J R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–698
   PubMed Web of Science ®Google Scholar
• Neyfakh A A, Serpinskaya A S, Chervonsky A V, Apasov S G, Kazarov A R. Multidrug-resistance phenotype of a subpopu-lation of T-lymphocytes without drug selection. Exp Cancer Res 1989; 185: 496–505
   Google Scholar
• Durie B G, Dalton W S. Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988; 68: 203–206
   PubMed Web of Science ®Google Scholar
• Gore M E, Shelby P J, Millar B, Maitland J, McElwain T J. The use of verapamil to overcome drug resistance to myeloma. Proc Am Soc Clin Oncol 1988; 7: 228
   Web of Science ®Google Scholar
• Ozols R F, Cunnion R E, Klecher R, Hamilton T C, Ostchega Y, Parrillo J E, Young R C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987; 5: 641–647
   PubMed Web of Science ®Google Scholar
• Slater L M, Murray S L, Wetzel M W, Wisdom R M, DuVall E M. Verapamil restoration of daunorubicin responsiveness in daun-orubicin-resistant Ehrlich ascites carcinoma. Clin Invest 1982; 70: 1131–1134
   Google Scholar
• Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristin resistance in P388 leukemia in-vivo and in-vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967–1972
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Kitani Y, Yoketa K, Tsukagaoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 1984; 44: 4303–4307
   PubMed Web of Science ®Google Scholar
• Ichikawa M, Yoshimura A, Furukawa T. Modulators of the human multidrug-transporter, P-glycoprotein, exist in the human plasma. Biochem Biophys Res Comm 1990; 166: 74–80
   PubMed Web of Science ®Google Scholar
• Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986; 47: 371–380
   PubMed Web of Science ®Google Scholar
• Scheper R J, Bulte J WM, Brakee J GP, Quak J J, van der Schott E, Balm A JM, Meijer C JLM, Broxterman H J, Kuiper C M, Lankelman J, Pinedo H M. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int J Cancer, 42: 389–394
   PubMedGoogle Scholar